Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Importance: Drug repurposing is potentially cost-effective, low risk, and necessary in psychiatric drug development. The availability of large, routine data sets provides the opportunity to evaluate the potential for currently used medication to benefit people with serious mental illness (SMI). Objective: To determine whether hydroxylmethyl glutaryl coenzyme A reductase inhibitors (HMG-CoA RIs), L-type calcium channel (LTCC) antagonists, and biguanides are associated with reduced psychiatric hospitalization and self-harm in individuals with SMI. Design, Setting, and Participants: These within-individual cohort studies of patients with SMI compared rates of psychiatric hospitalization and self-harm during periods of exposure and nonexposure to the study drugs, with adjusting for a number of time-varying covariates. Participants included 142 691 individuals from the entire population of Sweden with a diagnosis of bipolar disorder (BPD), schizophrenia, or nonaffective psychosis (NAP) who were 15 years or older and who were treated with psychiatric medication from October 1, 2005, through December 31, 2016. Data were analyzed from April 1 through August 31, 2018. Interventions: Treatment with HMG-CoA RIs, LTCC antagonists, or biguanides. Main Outcomes and Measures: Psychiatric hospitalizations and self-harm admissions. Results: Among the 142 691 eligible participants, the HMG-CoA RI exposure periods were associated with reduced rates of psychiatric hospitalization in BPD (adjusted hazard ratio [aHR], 0.86; 95% CI, 0.83-0.89; P < .001), schizophrenia (aHR, 0.75; 95% CI, 0.71-0.79; P < .001), and NAP (aHR, 0.80; 95% CI, 0.75-0.85; P < .001) and reduced self-harm rates in BPD (aHR, 0.76; 95% CI, 0.66-0.86; P < .001) and schizophrenia (aHR, 0.58; 95% CI, 0.45-0.74; P < .001). Exposure to LTCC antagonists was associated with reduced rates of psychiatric hospitalization and self-harm in subgroups with BPD (aHRs, 0.92 [95% CI, 0.88-0.96; P < .001] and 0.81 [95% CI, 0.68-0.95; P = .01], respectively), schizophrenia (aHRs, 0.80 [95% CI, 0.74-0.85; P < .001] and 0.30 [95% CI, 0.18-0.48; P < .001], respectively), and NAP (aHRs, 0.89 [95% CI, 0.83-0.96; P = .002] and 0.56 [95% CI, 0.42-0.74; P < .001], respectively). During biguanide exposure, psychiatric hospitalization rates were reduced in subgroups with BPD (aHR, 0.80; 95% CI, 0.77-0.84; P < .001), schizophrenia (aHR, 0.73; 95% CI, 0.69-0.77; P < .001), and NAP (aHR, 0.85; 95% CI, 0.79-0.92; P < .001), and self-harm was reduced in BPD (aHR, 0.73; 95% CI, 0.62-0.84; P < .001) and schizophrenia (aHR, 0.64; 95% CI, 0.48-0.85; P < .001). Conclusions and Relevance: This study provides additional evidence that exposure to HMG-CoA RIs, LTCC antagonists, and biguanides might lead to improved outcomes for individuals with SMI. Given the well-known adverse event profiles of these agents, they should be further investigated as repurposed agents for psychiatric symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fixed Effects Regression Models
Allison, P. (2009) · doi:10.4135/9781412993869 · Cited by 3,999
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017) · BMJ · doi:10.1136/bmj.j2099 · Cited by 1,703
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Self-citationEvaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses
Ekholm, B., Ekholm, A., Adolfsson, R., Vares, M., Ösby, U., Sedvall, G. C., & Jönsson, E. G. (2005) · Nordic Journal of Psychiatry · doi:10.1080/08039480500360906 · Cited by 242
Hollander, A.-C., Dal, H., Lewis, G., Magnusson, C., Kirkbride, J. B., & Dalman, C. (2016) · BMJ · doi:10.1136/bmj.i1030 · Cited by 240
Self-citationOsborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200
Self-citationYoung cases of schizophrenia identified in a national inpatient register
Dalman, C., Broms, J., Cullberg, J., & Allebeck, P. (2002) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-002-0582-3 · Cited by 192
Self-citationSong, J., Sjölander, A., Joas, E., Bergen, S. E., Runeson, B., Larsson, H., Landén, M., & Lichtenstein, P. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16050542 · Cited by 147
Adverse Effects of Statins - Myths and Reality
Simic, I., & Reiner, Z. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612820666141013134447 · Cited by 126
Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
Ying, M., Maruschak, N., Mansur, R., Carvalho, A., Cha, D., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130205514 · Cited by 29 · cited 1×
“of study drug exposure periods, median (IQR) 5 (3-11) 3 (3-7) 5 (3-11) 5 (3-9) 3 (3-7) 5 (3-10) 5 (3-9) 4 (3-7) 5 (3-9)”
Cited by
Interoceptive pathways to understand and treat mental health conditions
Nord, C. L., & Garfinkel, S. N. (2022) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.03.004 · Cited by 199
“In a recent demonstration of this in 142 691 patients with bipolar disorder, schizophrenia, or nonaffective psychosis, exposure to hydroxylmethyl glutaryl coenzyme A reductase inhibitors (statins, used to reduce cholesterol and heart disease), L-type calcium channel antagonists (used to reduce blood pressure), and big…”
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Costello, H., Roiser, J. P., & Howard, R. (2023) · Psychological Medicine · doi:10.1017/s003329172200397x · Cited by 60
“Epidemiological evidence has found an association between L-type calcium channel antagonist use (e.g. verapamil hydrochloride) and reduced rates of psychiatric hospitalisation and self-harm in bipolar disorder (Hayes et al., 2019).”
Metadata
- Authors
- Hayes, J. F., Lundin, A., Wicks, S., Lewis, G., Wong, I. C. K., Osborn, D. P. J., & Dalman, C.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2019-04-01
- Volume
- 76
- Issue
- 4
- Pages
- 382
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2910557287
- Cited by
- 67
- References
- 14
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.